Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

ClinicalTrials.gov ID: NCT00865228

Public ClinicalTrials.gov record NCT00865228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg in the Morning vs Lapaquistat Acetate 100 mg in the Evening vs Lapaquistat Acetate 50 mg Twice Daily vs Placebo in Subjects With Hypercholesterolemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.

Study identification

NCT ID
NCT00865228
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Takeda
Industry
Enrollment
224 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2007 (Type not available)
Primary completion
Nov 2007 (Actual)
Completion
Nov 2007 (Actual)
Last update posted
May 24, 2012

2007

United States locations

U.S. sites
22
U.S. states
12
U.S. cities
22
Facility City State ZIP Site status
Not listed Long Beach California — —
Not listed Sacramento California — —
Not listed San Diego California — —
Not listed Hollywood Florida — —
Not listed Jacksonville Florida — —
Not listed New Port Richey Florida — —
Not listed Chicago Illinois — —
Not listed Wichita Kansas — —
Not listed Louisville Kentucky — —
Not listed Margate City New Jersey — —
Not listed Charlotte North Carolina — —
Not listed Raleigh North Carolina — —
Not listed Statesville North Carolina — —
Not listed Wilmington North Carolina — —
Not listed Winston-Salem North Carolina — —
Not listed Medford Oregon — —
Not listed Perkasie Pennsylvania — —
Not listed Sellerville Pennsylvania — —
Not listed Bristol Tennessee — —
Not listed Norfolk Virginia — —
Not listed Richmond Virginia — —
Not listed Madison Wisconsin — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00865228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 24, 2012 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00865228 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →